Friederike Schlürmann
-
- Prostate Cancer Treatment and Research 9
- Renal cell carcinoma treatment 2
- Prostate Cancer Diagnosis and Treatment 2
-
- PARP inhibition in cancer therapy 7
- Cancer Immunotherapy and Biomarkers 3
- Pancreatic and Hepatic Oncology Research 1
-
- Cancer, Lipids, and Metabolism 1
-
- Radiopharmaceutical Chemistry and Applications 5
Friederike Schlürmann
11 papers receiving 261 citations
Hit Papers
Peers
Comparison fields: 5 of 28
- Pulmonary and Respiratory Medicine 217
- Oncology 162
- Cancer Research 67
- Radiology, Nuclear Medicine and Imaging 35
- Molecular Biology 84
Countries citing papers authored by Friederike Schlürmann
This map shows the geographic impact of Friederike Schlürmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Friederike Schlürmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Friederike Schlürmann more than expected).
Fields of papers citing papers by Friederike Schlürmann
This network shows the impact of papers produced by Friederike Schlürmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Friederike Schlürmann. The network helps show where Friederike Schlürmann may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Friederike Schlürmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 9 | |
| 5 | Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trialbreakdown → | 2023 | 132 |
| 6 | 2023 | 31 | |
| 7 | 2022 | 2 | |
| 8 | 2022 | 6 | |
| 9 | 2022 | 53 | |
| 10 | 2020 | 7 | |
| 11 | 2018 | 17 | |
| 12 | 2017 | 0 |
About Friederike Schlürmann
Friederike Schlürmann is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 12 papers that have together received 262 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (9 papers), PARP inhibition in cancer therapy (7 papers), Radiopharmaceutical Chemistry and Applications (5 papers), Cancer Immunotherapy and Biomarkers (3 papers), Renal cell carcinoma treatment (2 papers), Prostate Cancer Diagnosis and Treatment (2 papers), Cancer, Lipids, and Metabolism (1 paper) and Pancreatic and Hepatic Oncology Research (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (217 citations), Oncology (162 citations) and Cancer Research (67 citations). Friederike Schlürmann has collaborated with scholars based in France, Japan and Canada. Frequent co-authors include Mikio Sugimoto, Andrew J. Armstrong, Christian Poehlein, Fred Saad, Giuseppe Procopio, Emma Brown, Jae Young Joung, Noel W. Clarke, Niven Mehra and Mototsugu Oya. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.